Evaluation of Prognostic Impact of Serum Autoantibody in Patients with Metastatic Non-small-Cell Lung Cancer without EGFR activating mutation nor ALK fusion gene
Not Applicable
- Conditions
- on-Small-Cell Lung Cancer
- Registration Number
- JPRN-UMIN000016837
- Lead Sponsor
- Dept. of Thoracic Oncology, Kansai Medical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
Not provided
Exclusion Criteria
1. Concomitant other malignancy 2. Life expectancy <= 3 months 3. Use of steroid hormone, immunosuppressant, or biologic drug within 4 weeks at the time of enrollment 4. Severe active infection or poorly controlled disease ( e.g. hypertension, diabetes mellitus, cardiac disorder, gastro-intestinal bleeding, and so on) 5. Pregnant, possibly pregnant or lactating woman 6. Requiring radiation therapy to brain, mediastinum, or lung 7. Concomitant obvious interstitial lung disease on chest computed tomography 8. Poorly controlled malignant effusion requiring drainage 9. Otherwise determined by the investigator or the attending physician to be unsuitable as a subject in this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method